Journal: Frontiers in Pharmacology

Article Title: Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation

doi: 10.3389/fphar.2025.1514997

Figure Lengend Snippet: Molecular docking pattern of Curcumol with target proteins. (A) ALB (B) STAT3 (C) HSP90AA1 (D) HSP90AB1 (E) SRC.

Article Snippet: The following primary antibodies were used: PI3K (1:1,000, CST), p-PI3K (1:1,000, Abcam), AKT (1:1,000, CST), p-AKT (Ser473) (1:2,000, CST), JAK2 (1:1,000, CST), p-JAK2 (1:1,000, CST), STAT3 (1:2,000, Proteintech), p-STAT3 (1:2,000, BOSTER), β-actin (1:10,000, Affinity).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation

doi: 10.3389/fphar.2025.1514997

Figure Lengend Snippet: Relationship between differentially expressed core targets and immune cell infiltration. (A) ALB (B) STAT3 (C) HSP90AA1 (D) HSP90AB1 (E) SRC.

Article Snippet: The following primary antibodies were used: PI3K (1:1,000, CST), p-PI3K (1:1,000, Abcam), AKT (1:1,000, CST), p-AKT (Ser473) (1:2,000, CST), JAK2 (1:1,000, CST), p-JAK2 (1:1,000, CST), STAT3 (1:2,000, Proteintech), p-STAT3 (1:2,000, BOSTER), β-actin (1:10,000, Affinity).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation

doi: 10.3389/fphar.2025.1514997

Figure Lengend Snippet: Analysis of tumor infiltrating immune cells and hub genes using the Cox proportional hazards model.

Article Snippet: The following primary antibodies were used: PI3K (1:1,000, CST), p-PI3K (1:1,000, Abcam), AKT (1:1,000, CST), p-AKT (Ser473) (1:2,000, CST), JAK2 (1:1,000, CST), p-JAK2 (1:1,000, CST), STAT3 (1:2,000, Proteintech), p-STAT3 (1:2,000, BOSTER), β-actin (1:10,000, Affinity).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation

doi: 10.3389/fphar.2025.1514997

Figure Lengend Snippet: Experimental verification of the function of Curcumol in Sorafenib-resistant HCC cells. (A) Effect of Sorafenib (5, 10, 15, 20, 30, 40, and 50 μM) on Huh7-R and HepG2-R cells viability. (B) Effect of Curcumol (31.25, 62.5, 125, 250, 500, and 1000 μM) on Huh7-R and HepG2-R cells viability. (C) Effect of Curcumol combined with Sorafenib (5, 10, 15, 20, 30, 40, and 50 μM) on Huh7-R and HepG2-R cells viability. (D) Colony formation assay of Huh7-R and HepG2-R cells treated with Curcumol, Sorafenib, and Curcumol combined with Sorafenib, respectively. (E) Flow cytometry detection of apoptosis analysis of Huh7-R and HepG2-R cells treated with Curcumol, Sorafenib, and Curcumol combined with Sorafenib, respectively. (F) Transwell assay was performed to detect the effect of Curcumol on the migratory ability of Huh7-R cells. (G) Transwell assay to detect the effect of Curcumol on the invasive ability of Huh7-R cells. (H) Cell scratch assay of Huh7-R cells treated with Curcumol, Sorafenib, and Curcumol combined with Sorafenib, respectively. (I) The protein expression levels of PI3K\AKT pathway and JAK/STAT3 pathway following intervention with Curcumol combined with Sorafenib. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The following primary antibodies were used: PI3K (1:1,000, CST), p-PI3K (1:1,000, Abcam), AKT (1:1,000, CST), p-AKT (Ser473) (1:2,000, CST), JAK2 (1:1,000, CST), p-JAK2 (1:1,000, CST), STAT3 (1:2,000, Proteintech), p-STAT3 (1:2,000, BOSTER), β-actin (1:10,000, Affinity).

Techniques: Colony Assay, Flow Cytometry, Transwell Assay, Wound Healing Assay, Expressing

Journal: Frontiers in Pharmacology

Article Title: Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation

doi: 10.3389/fphar.2025.1514997

Figure Lengend Snippet: Curcumol combined with sorafenib inhibited the tumor growth of Huh7-R cell xenografts in vivo . (A) The gross appearance of the tumors in xenografted mice. (B) The tumor weight of xenografted mice after 14 days of intervention. (C) Tumor volumes in xenograft mice after 7 and 14 days of intervention. (D) Body weight of xenografted mice before and after 14 days of intervention. (E) HE staining of tumors. Scar bar = 100 μm. (F) Ki67 staining of tumors. Scar bar = 100 μm. (G) TUNEL staining of tumors. Scar bar = 50 μm. (H, I) Tumor tissues were stained for p-AKT (H) , and p-STAT3 (I) . Scar bar = 100 μm *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: The following primary antibodies were used: PI3K (1:1,000, CST), p-PI3K (1:1,000, Abcam), AKT (1:1,000, CST), p-AKT (Ser473) (1:2,000, CST), JAK2 (1:1,000, CST), p-JAK2 (1:1,000, CST), STAT3 (1:2,000, Proteintech), p-STAT3 (1:2,000, BOSTER), β-actin (1:10,000, Affinity).

Techniques: In Vivo, Staining, TUNEL Assay